1. Hong Kong Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Wanjia Group Holdings Ltd.

Wanjia Group Holdings Ltd.

HHKEX:401
0.10
HKD
0.00
(0.00%)
47.06MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.43
12.71
9.5
8.01
5.98
2.14
0.54
0.37
0.16
0.22
0.25
0.26
0.23
- -
Basic EPS, GAAP
0.25
0.3
-4.69
-0.08
-0.16
-0.34
-0.38
-0.08
-0.01
-0.07
- -
-0.06
-0.01
- -
Free Cash Flow per Basic Share
-0.3
0.01
-0.09
1.09
0.03
0.23
-0.32
0.04
-0.01
-0.01
0.01
0.01
0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.8
6.34
1.66
1.35
1.14
0.97
0.43
0.23
0.24
0.18
0.17
0.11
0.1
0.1
Tangible Book Value per Share
-3.96
1.57
1.65
1.35
0.33
0.07
-0.05
0.1
0.1
0.11
0.1
0.07
0.06
0.06
Basic Weighted Avg Shares
165
165
165
165
165
165
177
260
694
694
694
694
694
694
Sales/Revenue/Turnover
1,885
2,096
1,568
1,322
986
353
96
97
114
155
174
181
162
- -
Operating Margin (%)
3.27
3.64
1.61
-0.02
-1.44
0.04
-12.75
-10.15
-1.84
-0.52
2.98
-8.51
-2.47
- -
Depreciation Expense
4
4
5
6
6
9
7
7
10
13
12
10
8
- -
Net Income, GAAP
42
49
-773
-14
-26
-56
-67
-21
-5
-51
2
-40
-7
- -
Effective Tax Rate (%)
30.94
33.85
- -
- -
- -
- -
- -
- -
- -
- -
21.06
- -
- -
- -
Profit Margin (%)
2.22
2.33
-49.31
-1.04
-2.62
-15.75
-69.02
-21.39
-3.98
-32.94
1.05
-22.08
-4.09
- -
Working Capital
-676
235
246
331
70
31
7
32
34
36
39
28
28
28
LT Debt
- -
- -
- -
77
- -
- -
- -
21
20
18
15
12
9
9
Total Equity
133
1,046
283
291
238
214
135
158
171
128
120
75
69
69
Return on Invested Capital (%)
- -
7.94
- -
- -
- -
- -
- -
- -
- -
- -
2.59
- -
- -
- -
Return on Capital (%)
- -
8.01
- -
- -
- -
- -
- -
- -
- -
- -
2.24
- -
- -
- -
Return on Common Equity (%)
- -
8.31
-117.19
-5.56
-12.56
-32
-54.53
-17.16
-2.78
-34.52
1.49
-41.71
-9.43
- -

Capital Structure

HKD

•

in mil. unless spec.
Sep'18
Sep'25
Mar'25
ST Debt
93
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
11
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
165
694
694
Market Capitalization
155
44
47

Working Capital

HKD

•

in mil. unless spec.
Sep'18
Sep'25
Mar'25
Total Current Assets
324
66
57
Cash, Cash Equivalents & STI
31
32
24
Accounts Receivable, Net
61
26
15
Inventories
82
8
10
Total Current Liabilities
273
32
29
Payables & Accruals
- -
- -
- -
ST Debt
93
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-11.45%
-13.88%
-8.73%
Free Cash Flow
-133.51%
-52.75%
68.34%
Net Income, GAAP
-148.22%
-307.47%
-83.45%
Sales/Revenue/Turnover
-11.84%
11.82%
-10.71%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
181
2025
- -
- -
162
2026
- -
- -
- -

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.06
2025
- -
- -
-0.01
2026
- -
- -
- -

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jia Jun Wang
Full Time Employees
183
Sector
Distribution services
Industry
Medical distributors
Address
Tower 1 Hong Kong Hong Kong
IPO Date
Sep 30, 2013
Website
wanjia-gp.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Wanjia Group Holdings Limited (0401.HK) is an investment holding company principally engaged in pharmaceutical wholesale and distribution business and hemodialysis treatment and consultancy service business in the People's Republic of China. The company operates through two main segments: the pharmaceutical wholesale and distribution business, which distributes pharmaceutical and related products to hospitals, healthcare institutions, pharmaceutical retail chain stores, independent pharmacies, outpatient departments of community hospitals, healthcare service stations, and clinics primarily in Fujian Province; and the hemodialysis treatment and consultancy service business, which provides kidney care services and operates multiple self-operated hemodialysis treatment centers across Guangdong Province. Founded in 2004 and headquartered in Kowloon, Hong Kong, with its registered office in the Cayman Islands, the Group employs approximately 181 staff and generates all revenue from external customers in the PRC, reporting its fiscal year from April to March in HKD. Recent operational developments include a 10.71% year-over-year revenue decline to HK$161.693 million for the year ended March 31, 2025, driven by economic slowdowns and reduced fixed payment rates from county medical security bureaus affecting hemodialysis services, alongside cost control measures that narrowed operating losses by 89.63%; additionally, in October 2025, subsidiary Wuhua Yongke Kidney Hemodialysis faced a 61-day temporary suspension of its medical insurance service agreement from November 1, 2025, due to prescription non-compliance, prompting internal rectification, staff monitoring enhancements, and patient redirection with no material financial impact anticipated; the company also appointed independent non-executive directors Ms. Chan Wing Shan Winsome and Ms. Xu Wei in September 2024 to restore full compliance with HKEX listing rules following prior resignations.